Discovery of a novel HLA-Cw*08 allele, Cw*0817.

Tissue Antigens

HLA Laboratory, Blood Systems Laboratories, Tempe, AZ 85282, USA.

Published: June 2009

This report describes the discovery and characterization of the HLA-Cw*0817 allele.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-0039.2009.01243.xDOI Listing

Publication Analysis

Top Keywords

discovery novel
4
novel hla-cw*08
4
hla-cw*08 allele
4
allele cw*0817
4
cw*0817 report
4
report describes
4
describes discovery
4
discovery characterization
4
characterization hla-cw*0817
4
hla-cw*0817 allele
4

Similar Publications

Deep learning-based design and experimental validation of a medicine-like human antibody library.

Brief Bioinform

November 2024

Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceutical Inc., 900 Ridgebury Road, Ridgefield, CT 06877, United States.

Antibody generation requires the use of one or more time-consuming methods, namely animal immunization, and in vitro display technologies. However, the recent availability of large amounts of antibody sequence and structural data in the public domain along with the advent of generative deep learning algorithms raises the possibility of computationally generating novel antibody sequences with desirable developability attributes. Here, we describe a deep learning model for computationally generating libraries of highly human antibody variable regions whose intrinsic physicochemical properties resemble those of the variable regions of the marketed antibody-based biotherapeutics (medicine-likeness).

View Article and Find Full Text PDF

Structure-based identification of HNF4α agonists: Rosmarinic acid as a promising candidate for NAFLD treatment.

Comput Struct Biotechnol J

December 2024

National Vaccine Innovation Platform, Scholl of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

Unlabelled: The prevention and treatment of metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD), have emerged as critical global health challenges. Current lipid-lowering pharmacotherapies are associated with side effects, including hepatotoxicity, rhabdomyolysis, and decreased erythrocyte counts, underscoring the urgent need for safer therapeutic alternatives. Hepatocyte nuclear factor 4α (HNF4α) has been identified as a pivotal regulator of lipid metabolism, making it an attractive target for drug development.

View Article and Find Full Text PDF

Platelet-derived growth factor alpha (PDGFRA) plays a significant role in various malignant tumors. PDGFRA expression boosts thyroid cancer cell proliferation and metastasis. Radiorefractory thyroid cancer is poorly differentiated, very aggressive, and resistant to radioiodine therapy.

View Article and Find Full Text PDF

Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy, and current postoperative prognostic assessment methods remain unsatisfactory, underlining the urgent to develop a reliable approach for precision medicine. Given the similarities with gametogenesis, cancer/testis genes (CTGs) are acknowledged for regulation unrestrained multiplication and immune microenvironment during oncogenic processes. These processes are associated with advanced disease and poorer prognosis, indicating that CTGs could serve as ideal prognostic biomarkers in ESCC.

View Article and Find Full Text PDF

Itaconate, an endogenous immunomodulator from the tricarboxylic acid (TCA) cycle, shows therapeutic effects in various disease models, but is highly polar with poor cellular permeability. We previously reported a novel, topical itaconate derivative, SCD-153, for the treatment of alopecia areata. Here, we present the discovery of orally available itaconate derivatives for systemic and skin disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!